Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia

Biosimilar Agreement Covers Taiwan And Key Asian Markets

 
• By Dean Rudge

Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).

Asia - Pacific
The combined size of Lotus’ markets of interest is roughly US$30m • Source: Shutterstock

More from Deals

More from Business